Back to Search
Start Over
Biophysical characterization of the oligomeric states of recombinant Immunoglobulins type-M and their C1q binding kinetics by Biolayer Interferometry
- Source :
- Frontiers in Bioengineering and Biotechnology, Frontiers in Bioengineering and Biotechnology, 2022, 10, pp.816275. ⟨10.3389/fbioe.2022.816275⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- The Immunoglobulins type-M (IgMs) are one of the first antibody classes mobilized during immune responses against pathogens and tumor cells. Binding to specific target antigens enables the interaction with the C1 complex which strongly activates the classical complement pathway. This biological function is the basis for the huge therapeutic potential of IgMs but due to their high oligomeric complexity,in vitroproduction, biochemical and biophysical characterizations are challenging. In the present study, we present recombinant production of two IgM models (IgM617 and IgM012) in pentameric and hexameric states and the evaluation of their polymer distribution using different biophysical methods (AUC, SEC-MALLS, Mass Photometry and Transmission Electron Microscopy). Each IgM oligomer has individual specific expression pattern and yield with different protein quality likely due to intrinsic IgM properties and patterning. Nevertheless, the purified recombinant IgMs retain their ability to activate complement in a C1q dependent manner. And more importantly, a new method to evaluate their functional quality attribute by characterizing the kinetics of C1q binding to recombinant IgM has been developed using BioLayer Interferometry (BLI). We show that recombinant IgMs possess similar C1q binding properties as IgMs purified from human plasma.
- Subjects :
- biophysical characterization
IgM
Histology
immunoglobulins
Biomedical Engineering
Bioengineering
recombinant expression
Oligomer
[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity
law.invention
03 medical and health sciences
Classical complement pathway
chemistry.chemical_compound
0302 clinical medicine
Immune system
Antigen
law
complement
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]
C1q
030304 developmental biology
0303 health sciences
biology
[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM]
Chemistry
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
Receptor–ligand kinetics
In vitro
3. Good health
[SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics
protein–protein interaction
biolayer interferometry
[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology
biology.protein
Biophysics
Recombinant DNA
Antibody
Biotechnology
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 22964185
- Database :
- OpenAIRE
- Journal :
- Frontiers in Bioengineering and Biotechnology, Frontiers in Bioengineering and Biotechnology, 2022, 10, pp.816275. ⟨10.3389/fbioe.2022.816275⟩
- Accession number :
- edsair.doi.dedup.....734b27e04fcb3aab4e9c44e713cbeaca
- Full Text :
- https://doi.org/10.3389/fbioe.2022.816275⟩